Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study

Alentis Therapeutics announced results from the multiple-ascending dose part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1.